Improved Efficacy of Cancer Drugs and Cost Savings Driving Demand for
Continuous Infusion of Chemotherapy
NEW YORK, March 18 /PRNewswire-FirstCall/ -- InfuSystem Holdings, Inc. (OTC Bulletin Board: INHI; INHIW; INHIU), the leading provider of ambulatory infusion pump services for administering chemotherapy, today announced financial results for the fourth quarter of 2007. InfuSystem Holdings' results include results of operations for InfuSystem, Inc. from October 26, 2007 through December 31, 2007.
InfuSystem, Inc. supplies oncology practices, hospitals and their
patients with ambulatory infusion pumps and related services. InfuSystem
also provides 24/7 nursing support to address questions that patients may
have about their pump treatment or other questions related to the pump.
Continuous infusion pumps allow for the gradual delivery of a drug over a
period of days in the privacy of one's home, compared to bolus infusion
chemotherapy treatments that are given in a single high dose over a short
period of time. Improved efficacy of the drugs, patient comfort,
reimbursement to doctors for appropriate services and continuity of care
all play a role in the growing trend toward this form of treatment. The
company has approximately 60% penetration of oncologist practices in the
United States, and agreements with managed care organizations covering over
125 million managed care lives.
-- Completed the acquisition of InfuSystem, Inc.
-- Former president and co-founder of InfuSystem, Steve Watkins, appointed
chief executive officer
-- Sean M. Whelan, CPA, hired as chief financial officer
-- David M. Haar hired as vice president of marketing
-- Scott L. Chesky appointed vice president of strategic development
Mr. Sean McDevitt, chairman of the board, commented, "Following the
acquisition of InfuSystem, we are now well underway to completing all of
|SOURCE InfuSystem Holdings, Inc.|
Copyright©2008 PR Newswire.
All rights reserved